Medical Isotopes Market Size, Share, Growth, and Industry Analysis, By Type (Tc-99m, I-131, Lu-177, Mo-99, Iodine-125, Holmium-166) By Application (Nuclear Therapy, Equipment Radioactive Source, Diagnosis) Regional Forecast From 2026-2035

•   
•   
  

  Download Free Sample to learn more about this report

    

MEDICAL ISOTOPES MARKET OVERVIEW

The global Medical Isotopes Market is estimated to be valued at USD 0.98 Billion in 2026. The market is projected to reach USD 1.93 Billion by 2035, expanding at a CAGR of 7.8% from 2026 to 2035.

The Medical Isotopes Market is expanding significantly due to increasing demand for nuclear diagnostics, cancer treatment procedures, and advanced molecular imaging technologies. More than 48 million nuclear medicine procedures were performed globally during 2025, with Tc-99m accounting for 79% of all diagnostic isotope utilization. Hospitals and diagnostic centers increased isotope consumption by 23% because oncology imaging procedures expanded rapidly across developed healthcare systems. North America represented 41% of global medical isotope usage due to strong nuclear medicine infrastructure and increasing PET scan adoption. Lu-177 demand increased by 31% during 2025 because targeted radionuclide therapies gained wider approval for prostate and neuroendocrine tumor treatment applications.

The United States Medical Isotopes Market demonstrated strong growth during 2025 because more than 20 million nuclear imaging procedures were performed across hospitals and specialty diagnostic facilities. Tc-99m represented 82% of diagnostic isotope demand due to increasing SPECT imaging utilization for cardiovascular and oncology diagnosis. Approximately 6,000 hospitals and imaging centers in the United States actively used medical isotopes during 2025. Lu-177 therapy procedures increased by 29% because precision cancer treatment adoption accelerated across oncology centers. PET scan procedures exceeded 4.2 million annually, while isotope-based cancer diagnosis improved early detection efficiency by 26%. Domestic Mo-99 production capacity also increased by 18%, improving isotope supply reliability throughout the healthcare system.

KEY FINDINGS

LATEST TRENDS

Throughout The Forecast Period, the Cardiology Segment Is Anticipated To Have A Sizable Market Share

The Medical Isotopes Market is witnessing major technological advancements due to increasing demand for precision oncology, molecular imaging, and targeted radionuclide therapies. During 2025, Tc-99m maintained dominance with 79% share of diagnostic isotope utilization because SPECT imaging procedures exceeded 32 million globally. Lu-177 demand increased by 31% because healthcare providers expanded targeted cancer treatment programs for prostate and neuroendocrine tumors. PET imaging procedures improved by 24% during 2025 due to rising FDG-based diagnostic utilization across oncology and neurology applications.

Cyclotron-based isotope production facilities increased by 19% globally because healthcare systems sought alternatives to aging reactor infrastructure. North America represented 41% of global medical isotope utilization due to advanced nuclear medicine capabilities and strong diagnostic imaging infrastructure. Europe accounted for 29% of worldwide nuclear medicine procedures during 2025. Diagnostic applications represented 52% of total isotope demand, while nuclear therapy contributed 38%. AI-assisted imaging systems improved lesion detection accuracy by 21%, enhancing clinical diagnostic efficiency. Healthcare facilities also adopted automated radiopharmacy systems, improving isotope preparation efficiency by 18% and reducing contamination risks significantly during 2025.

•   
•   
  

  Download Free Sample to learn more about this report

    

MEDICAL ISOTOPES MARKET SEGMENTATION

By Type

According to type, the market can be segmented into Tc-99m, I-131, Lu-177, Mo-99, Iodine-125, Holmium-166

• Tc-99m: Tc-99m dominated the Medical Isotopes Market during 2025 with 79% share of diagnostic isotope utilization because it remained the preferred isotope for SPECT imaging procedures. More than 32 million Tc-99m-based diagnostic scans were conducted globally during 2025 due to rising cardiovascular and oncology imaging demand. Tc-99m imaging improved lesion detection efficiency by 24% across oncology applications. North America accounted for 43% of Tc-99m utilization because hospitals and imaging centers maintained advanced nuclear medicine infrastructure. Tc-99m half-life of 6 hours supported efficient imaging procedures while minimizing patient radiation exposure. Automated radiopharmacy preparation systems improved Tc-99m handling efficiency by 18% during 2025. Demand for Tc-99m increased significantly due to growing elderly populations and rising chronic disease diagnosis rates globally.

• I-131: I-131 accounted for 11% of global medical isotope demand during 2025 because thyroid cancer treatment and hyperthyroidism management procedures expanded globally. More than 2.8 million I-131 treatment procedures were conducted during 2025 due to increasing thyroid disease prevalence. Nuclear therapy applications represented 89% of I-131 utilization because radioactive iodine therapy remained highly effective for thyroid tissue targeting. Europe contributed 31% of global I-131 usage because nuclear oncology programs expanded significantly across regional healthcare systems. Hospital-based isolation facilities increased by 14% during 2025 to support radioactive iodine treatment protocols safely. I-131 therapy improved thyroid cancer management outcomes by 27%, supporting continued clinical adoption among oncology and endocrinology specialists worldwide.

• Lu-177: Lu-177 represented 8% of the Medical Isotopes Market during 2025 because targeted radionuclide therapy adoption increased rapidly across oncology treatment programs. Lu-177 demand expanded by 31% during 2025 due to increasing prostate cancer therapy procedures globally. More than 480,000 Lu-177 treatment cycles were performed during 2025 because precision oncology adoption accelerated across advanced healthcare systems. North America accounted for 39% of Lu-177 utilization because specialized oncology centers expanded radionuclide treatment infrastructure. Combination therapies integrating Lu-177 with molecular targeting agents improved treatment precision by 22%. Healthcare providers increased investments in theranostic technologies, supporting Lu-177 integration into personalized cancer treatment programs globally during 2025.

• Mo-99: Mo-99 represented 64% of global isotope production activity during 2025 because it serves as the parent isotope for Tc-99m generation. More than 95% of Tc-99m supply depended on Mo-99 production during 2025. Reactor-based Mo-99 production facilities accounted for 72% of total manufacturing output globally. North America and Europe collectively contributed 61% of Mo-99 production infrastructure during 2025 because advanced nuclear facilities supported isotope generation. Cyclotron-based Mo-99 alternatives increased by 19%, reducing dependence on aging nuclear reactors. Supply chain reliability improved by 18% due to expanded domestic production initiatives. Healthcare systems prioritized Mo-99 availability because diagnostic imaging continuity remained essential for nuclear medicine procedures worldwide.

• Iodine-125: Iodine-125 accounted for 5% of medical isotope demand during 2025 because brachytherapy procedures and diagnostic applications remained clinically significant. More than 320,000 Iodine-125 seed implant procedures were conducted globally during 2025 due to increasing prostate cancer treatment adoption. Brachytherapy applications represented 83% of Iodine-125 utilization because localized radiation delivery improved treatment precision significantly. Asia-Pacific contributed 28% of global Iodine-125 demand during 2025 due to expanding oncology treatment infrastructure. Implantation accuracy improved by 21% through image-guided brachytherapy technologies. Healthcare facilities increased adoption of minimally invasive cancer therapies, supporting growing Iodine-125 demand throughout oncology treatment programs worldwide.

• Holmium-166: Holmium-166 represented 3% of global medical isotope utilization during 2025 because targeted liver cancer therapies and microsphere treatments expanded steadily. More than 95,000 Holmium-166 procedures were performed globally during 2025 due to rising hepatic oncology treatment demand. Nuclear therapy applications accounted for 91% of Holmium-166 utilization because selective internal radiation therapy improved tumor targeting efficiency. Europe represented 34% of Holmium-166 treatment activity because specialized oncology centers expanded radionuclide therapy programs. MRI-visible microsphere technologies improved treatment monitoring accuracy by 23%. Healthcare providers increasingly adopted Holmium-166 therapies because liver-directed radiation treatment demonstrated improved patient management outcomes during 2025.

By Application

Based on application, the market can be divided into Nuclear Therapy, Equipment Radioactive Source, and Diagnosis. Nuclear Therapy will be the leading segment.

• Nuclear Therapy: Nuclear therapy accounted for 38% of the Medical Isotopes Market during 2025 because targeted radionuclide treatments expanded significantly across oncology applications. More than 5.6 million nuclear therapy procedures were performed globally during 2025 due to increasing cancer incidence and precision oncology adoption. Lu-177 and I-131 represented 71% of therapeutic isotope utilization because prostate cancer and thyroid disease treatment programs expanded rapidly. North America contributed 37% of global nuclear therapy demand due to advanced oncology infrastructure. Targeted radionuclide therapies improved treatment precision by 24%, reducing damage to healthy tissue significantly. Specialized oncology centers increased isotope therapy installations by 18% during 2025.

• Equipment Radioactive Source: Equipment radioactive source applications represented 10% of global medical isotope demand during 2025 because radiotherapy systems and calibration equipment required stable isotope sources. More than 14,000 healthcare imaging systems globally utilized radioactive calibration sources during 2025. Hospital radiation therapy equipment accounted for 62% of radioactive source demand because precise imaging calibration remained essential for diagnostic accuracy. Europe contributed 29% of equipment radioactive source utilization due to advanced radiotherapy infrastructure. Radiation calibration precision improved by 19% through enhanced isotope integration technologies. Healthcare facilities increasingly upgraded imaging systems, supporting steady demand for reliable radioactive equipment sources during 2025.

• Diagnosis: Diagnosis dominated the Medical Isotopes Market with 52% share during 2025 because PET and SPECT imaging procedures expanded rapidly across oncology and cardiology applications. More than 42 million isotope-based diagnostic scans were conducted globally during 2025 due to rising chronic disease prevalence. Tc-99m represented 79% of diagnostic isotope utilization because hospitals and imaging centers relied heavily on nuclear imaging technologies. North America accounted for 41% of diagnostic isotope demand because advanced imaging infrastructure remained highly developed. AI-assisted imaging systems improved lesion detection accuracy by 21%, enhancing clinical diagnosis efficiency. PET imaging adoption increased by 24% during 2025 because precision oncology diagnostics expanded globally.

MARKET DYNAMICS

Driving Factor

Rising demand for cancer diagnosis and nuclear imaging procedures.

The Medical Isotopes Market is strongly driven by increasing cancer incidence, rising adoption of molecular imaging, and growing demand for precision oncology therapies. More than 48 million nuclear medicine procedures were conducted globally during 2025 due to increasing use of isotope-based diagnostic imaging technologies. Tc-99m represented 79% of diagnostic isotope demand because SPECT imaging remained essential for cardiovascular and oncology diagnostics. PET imaging procedures increased by 24% globally during 2025 due to expanding FDG-based cancer diagnosis programs. North America accounted for 41% of medical isotope utilization because hospitals and specialty imaging centers invested heavily in nuclear medicine infrastructure. Lu-177 therapy adoption improved by 31%, supporting targeted treatment programs for advanced prostate and neuroendocrine cancers across healthcare systems worldwide.

Restraining Factor

Limited isotope supply and transportation challenges.

The Medical Isotopes Market faces restraints associated with isotope shortages, short half-life limitations, and strict transportation regulations. Approximately 19% of healthcare facilities experienced isotope supply disruptions during 2025 because aging reactor infrastructure reduced production consistency. Transportation restrictions affected 17% of international isotope shipments due to radioactive material handling requirements. Mo-99 production interruptions delayed diagnostic imaging schedules in several regions because reactor maintenance reduced isotope availability. High compliance costs increased operational complexity for isotope manufacturers and radiopharmacies globally. Short isotope half-lives also created logistical challenges because Tc-99m loses nearly 50% activity every 6 hours. Rural healthcare facilities experienced delayed isotope access, reducing nuclear medicine adoption across underserved healthcare regions during 2025.

Expansion of targeted radionuclide therapies.

Opportunity

The Medical Isotopes Market presents strong opportunities due to increasing demand for targeted radionuclide therapies and personalized oncology treatments. Lu-177 utilization increased by 31% during 2025 because precision cancer therapies demonstrated improved treatment outcomes for metastatic prostate cancer patients. AI-assisted imaging improved diagnostic accuracy by 21%, supporting expanded nuclear medicine adoption across hospitals and specialty clinics. Cyclotron-based isotope production capacity increased by 19% globally, improving decentralized isotope availability and reducing supply chain dependence.

High infrastructure and regulatory compliance requirements.

Challenge

The Medical Isotopes Market continues facing challenges associated with high infrastructure costs, regulatory complexity, and radioactive waste management. Nuclear medicine facilities require specialized shielding systems, increasing installation expenses by 22% during 2025. Regulatory inspections affected 16% of isotope distribution facilities because radioactive handling standards became stricter globally. Healthcare providers faced staffing shortages because trained nuclear medicine technologists represented only 4% of specialized diagnostic personnel globally. Radioactive waste disposal procedures increased operational complexity for hospitals and isotope production facilities.

•   
•   
  Download Free Sample to learn more about this report

    

MEDICAL ISOTOPES MARKET REGIONAL INSIGHTS

• North America

North America dominated the Medical Isotopes Market with 41% share during 2025 because the region maintained advanced nuclear medicine infrastructure, strong radiopharmaceutical manufacturing capacity, and high diagnostic imaging utilization. The United States accounted for 84% of regional isotope demand due to more than 20 million nuclear medicine procedures conducted annually. Tc-99m represented 82% of regional diagnostic isotope utilization because SPECT imaging remained widely adopted across cardiology and oncology departments. PET imaging procedures exceeded 4.2 million during 2025 due to rising oncology screening programs.

Lu-177 therapy adoption increased by 29% across North America because healthcare providers expanded targeted prostate cancer treatment capabilities. More than 6,000 hospitals and imaging centers actively used medical isotopes throughout the region during 2025. Domestic Mo-99 production capacity improved by 18%, reducing supply disruptions and strengthening isotope availability. Automated radiopharmacy systems increased by 16%, improving isotope preparation efficiency and reducing contamination risks. AI-assisted diagnostic imaging improved lesion detection accuracy by 21%, supporting precision oncology adoption across regional healthcare systems. North America also maintained strong investment in cyclotron infrastructure and decentralized isotope production technologies during 2025.

Europe

Europe accounted for 29% of the Medical Isotopes Market during 2025 because the region maintained strong nuclear medicine capabilities and advanced radiopharmaceutical research programs. Germany, France, the United Kingdom, and the Netherlands contributed 67% of regional isotope demand due to expanding oncology imaging and radionuclide therapy programs. Tc-99m represented 76% of diagnostic isotope usage because SPECT imaging remained highly integrated into European healthcare systems. More than 11 million nuclear medicine procedures were conducted across Europe during 2025.

Lu-177 therapy procedures increased by 27% because oncology centers expanded precision radionuclide treatment programs for metastatic prostate cancer patients. Europe accounted for 34% of global Holmium-166 treatment activity due to increasing liver cancer therapy adoption. Cyclotron-based isotope production capacity improved by 21%, reducing dependence on imported isotopes and strengthening supply reliability. Diagnostic imaging centers increased PET scan installations by 18% during 2025 because molecular imaging demand continued expanding. AI-supported radiology platforms improved workflow efficiency by 17%, enhancing diagnostic accuracy and clinical productivity throughout European nuclear medicine facilities.

• Asia-Pacific

Asia-Pacific represented 23% of the Medical Isotopes Market during 2025 because healthcare infrastructure investment and cancer diagnostic procedures increased rapidly throughout the region. China, Japan, India, and South Korea contributed 74% of regional isotope demand due to expanding oncology treatment infrastructure and growing healthcare access. PET imaging procedures increased by 26% during 2025 because hospitals and diagnostic centers expanded molecular imaging capabilities significantly. Tc-99m accounted for 73% of regional diagnostic isotope utilization due to increasing SPECT imaging adoption.

Cyclotron facility installations increased by 22% throughout Asia-Pacific because governments and healthcare organizations prioritized domestic isotope production capabilities. Nuclear therapy procedures improved by 24% because targeted radionuclide treatment programs expanded rapidly across oncology centers. India increased radiopharmacy facility development by 19%, supporting regional isotope availability during 2025. Healthcare providers also adopted AI-assisted imaging systems, improving diagnostic efficiency by 18%. Growing elderly populations and rising cancer incidence continued driving demand for advanced nuclear imaging technologies throughout Asia-Pacific healthcare systems during 2025.

• Middle East & Africa

The Middle East & Africa accounted for 7% of the Medical Isotopes Market during 2025 because healthcare modernization and oncology infrastructure development improved regional isotope utilization. Gulf countries represented 63% of regional market activity due to increasing investment in PET imaging and cancer treatment facilities. Diagnostic applications accounted for 56% of isotope demand because nuclear imaging adoption expanded across major hospitals and specialty clinics. PET imaging procedures increased by 17% during 2025 because healthcare providers expanded oncology screening programs significantly.

Radiopharmacy installations improved by 14% throughout the Middle East during 2025 because healthcare systems prioritized localized isotope preparation capabilities. South Africa contributed 28% of regional isotope demand due to advanced diagnostic imaging infrastructure compared to neighboring African markets. Lu-177 therapy adoption increased by 16% because oncology centers expanded targeted radionuclide treatment programs. Healthcare facilities also improved isotope transportation systems, reducing delivery delays by 12%. Government healthcare investment and expanding cancer treatment infrastructure continued supporting regional Medical Isotopes Market growth during 2025.

LIST OF TOP MEDICAL ISOTOPES COMPANIES

• ORNL
• Polatom
• China National Nuclear Corporation
• NorthStar
• Niowave Inc.
• Center of Molecular Research
• LANL
• Cambridge Isotope Laboratories, Inc.
• Urenco
• Bruce Power
• Coqui RadioPharmaceuticals
• NTP Radioisotopes
• SHINE Technologies
• NRG
• IRE
• Eckert and Ziegler Strahlen

Top 2 Companies With Highest Market Share

• China National Nuclear Corporation: Accounted for 18% of global medical isotope production activity.
• NorthStar: Represented 13% of worldwide isotope supply activity.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investments in the Medical Isotopes Market increased significantly during 2025 because healthcare systems expanded nuclear medicine capabilities, cancer diagnosis infrastructure, and radionuclide therapy programs. More than 48 million nuclear medicine procedures globally encouraged hospitals and governments to increase isotope production investments. Cyclotron-based isotope manufacturing facilities increased by 19% during 2025 because healthcare providers sought alternatives to aging reactor infrastructure. North America accounted for 41% of global isotope utilization, supporting continued investment in radiopharmaceutical production and imaging system modernization.

Opportunities continue expanding within Lu-177 targeted therapies, AI-assisted imaging platforms, and decentralized isotope production technologies. Lu-177 demand improved by 31% during 2025 because precision oncology programs expanded rapidly across advanced healthcare systems. PET imaging installations increased by 18% globally due to rising molecular imaging adoption. Asia-Pacific healthcare providers expanded radiopharmacy infrastructure by 23%, supporting regional isotope availability and nuclear medicine adoption. Automated radiopharmacy systems improved isotope preparation efficiency by 18%, reducing contamination risks and improving workflow productivity. Emerging healthcare markets also demonstrated rising investment in oncology imaging centers and nuclear therapy treatment facilities during 2025.

NEW PRODUCT DEVELOPMENT

The Medical Isotopes Market is experiencing major product innovation involving targeted radionuclide therapies, advanced imaging isotopes, and automated radiopharmacy technologies. During 2025, AI-assisted nuclear imaging systems improved lesion detection accuracy by 21%, supporting precision oncology diagnosis and faster clinical interpretation. Lu-177 radiopharmaceutical development increased significantly because targeted prostate cancer treatment adoption expanded globally. Automated isotope preparation systems improved radiopharmacy workflow efficiency by 18%, reducing manual contamination risks and preparation errors.

Cyclotron-based isotope production technologies improved isotope purity levels by 22%, supporting decentralized production and reducing dependence on reactor-based supply chains. MRI-visible Holmium-166 microspheres improved liver cancer therapy monitoring accuracy by 23% during 2025. Portable radiopharmacy units increased by 14% because healthcare providers sought flexible isotope preparation solutions for regional hospitals. Tc-99m generator technologies also improved isotope extraction efficiency by 17%, supporting uninterrupted diagnostic imaging procedures. Advanced theranostic platforms integrating diagnostic and therapeutic isotopes further improved personalized oncology treatment capabilities during 2025.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, a nuclear medicine company launched an advanced Lu-177 radiopharmaceutical platform that improved targeted prostate cancer treatment precision by 24%.
• During 2023, a radiopharmacy manufacturer introduced an automated isotope preparation system reducing contamination risks by 18% across hospital nuclear medicine facilities.
• In 2024, a healthcare technology provider developed an AI-assisted PET imaging platform improving lesion detection accuracy by 21% during oncology diagnostics.
• In 2024, a medical isotope producer expanded cyclotron-based Mo-99 manufacturing capacity by 19%, improving regional isotope supply reliability significantly.
• In 2025, a radiopharmaceutical company launched MRI-visible Holmium-166 microspheres enhancing liver cancer therapy monitoring accuracy by 23%.

REPORT COVERAGE OF MEDICAL ISOTOPES MARKET

The Medical Isotopes Market report covers diagnostic isotopes, radionuclide therapies, radiopharmaceutical technologies, isotope production systems, and nuclear medicine applications across global healthcare industries. The report evaluates Tc-99m, I-131, Lu-177, Mo-99, Iodine-125, and Holmium-166 utilization trends throughout hospitals, oncology centers, diagnostic imaging facilities, and radiopharmacies. Diagnostic applications represented 52% of total isotope demand during 2025 because PET and SPECT imaging procedures expanded significantly across healthcare systems worldwide.

The report analyzes isotope production technologies, cyclotron infrastructure, radiopharmacy automation, and AI-assisted imaging developments influencing market expansion. North America accounted for 41% of global isotope utilization during 2025 due to advanced nuclear medicine infrastructure and strong radiopharmaceutical manufacturing capabilities. Regional analysis includes healthcare investment trends, oncology treatment adoption, isotope supply chains, and regulatory infrastructure across North America, Europe, Asia-Pacific, and Middle East & Africa. Competitive assessment evaluates isotope manufacturing capabilities, targeted radionuclide therapy development, and nuclear imaging innovation among leading Medical Isotopes Market participants globally.